Role of inflammation in intraplaque hemorrhage pathogenesis
Role of inflammation in intraplaque hemorrhage pathogenesis
批准号:
10392657
负责人:
Jenny E. Kanter
金额:
$82.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-01 至 2026-04-30
关键词:
3-DimensionalAchievementAddressAffectAntibodiesArterial Fatty StreakAtherosclerosisB-LymphocytesBlood VesselsCardiovascular systemCarotid Artery PlaquesCarotid EndarterectomyCause of DeathCellsCholesterolClinicalCoculture TechniquesCollaborationsComplementDataDevelopmentElementsEndothelial CellsEndotheliumErythrocytesEventExcisionFollow-Up StudiesGoalsGrowthGuidelinesHealth Care CostsHemoglobinHemorrhageHistologicHistologyHumanHypoxiaImageImaging TechniquesImmunoglobulin MIn VitroInflammationInflammatoryInvestigationKnowledgeLipidsLow-Density LipoproteinsMagnetic Resonance ImagingMeasuresMyocardial InfarctionNecrosisOxygenPathogenesisPathologyPatientsPermeabilityPersonsPlasmaProductionQuality of lifeResidual stateRiskRoleScanningSourceSpecimenStrokeTestingTissuesTunica AdventitiaUnited StatesVascular DiseasesVascular Permeabilitiesatheroprotectiveblood pressure controlcontrast enhancedcoronary plaquedensitydriving forcefollow-uphistological studiesin vivoinhibitor therapymacrophageneovascularizationneovasculaturenovelpreventresponsetherapeutic targettreatment responsetreatment strategyvasa vasorum
中文摘要
项目摘要
动脉粥样硬化性心血管疾病(ASCVD)仍然是美国的主要死亡原因。尽管
在促进积极抗动脉粥样硬化治疗的指南中,
使用他汀类药物和PCSK 9抑制剂联合治疗达到LDL-C显著降低(中位值30 mg/dL)的患者
疗法需要新的治疗策略来靶向LDL以外的机制,以减少这种残留
风险组织学研究表明,斑块新生血管构成了血管的主要入口,
炎症细胞进入斑块,并为斑块内炎症的形成和进展提供了主要来源。
出血(IPH)。IPH主要由斑块新生血管形成引起,是晚期动脉粥样硬化的共同特征。
动脉粥样硬化病变和导致斑块进展加速、斑块不稳定和
缺血性血管事件。我们发现斑块新生血管通透性(用Ktranss测量,
动态对比增强磁共振成像)与巨噬细胞含量密切相关,
大外膜Ktranss与IPH有关最近的研究表明,CD 163+巨噬细胞
与IPH相关,并可进一步促进导致IPH进展的新血管形成。另
另一方面,B1细胞来源的IgM可以抑制炎症和减少动脉粥样硬化,
与冠状动脉斑块体积和不稳定特征呈负相关。我们的初步数据显示
颈动脉IPH患者血浆IgM水平降低,B1细胞与IPH呈负相关
进展因此,我们建议研究B1细胞来源的IgM和B1细胞在IPH病理中的作用。
为了检验一个新的假设,即IPH患者B1细胞源性IgM水平降低,
保护性IgM减少导致无阻碍的IPH促进的炎症和新生血管
渗透性,从而加剧斑块进展,我们建议进行全面的研究,
包括:(1)组织学检查CEA标本,以确定斑块是否具有增加的Ktrans
和/或IPH具有较低密度的IgM和较高密度的CD 163+巨噬细胞;(2)纵向临床
在250名患者中进行的一项随访研究,以确定较低的IgM水平和B1细胞是否预测Ktranss的进展
和IPH患者的B1细胞是否产生IgM和对巨噬细胞的影响不同,
无IPH;(3)使用3D微血管进行内皮发芽和渗漏的体外机制研究,
确定IgM和B1细胞对RBC诱导的巨噬细胞和血管通透性变化的影响。
该提案利用最先进的成像技术来量化血管渗透性和IPH
和3D微血管,用于研究血红蛋白刺激的巨噬细胞和B1细胞和/或IgM如何影响
内皮功能相关的血管通透性。我们的研究将获得新的知识,以揭示炎症
IPH发病机制,并发现潜在的治疗靶点,以减少血管
渗透性,以防止IPH及其进展,这将最终降低残余ASCVD风险。
英文摘要
PROJECT SUMMARY
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in the US. Despite
guidelines promoting aggressive anti-atherosclerotic therapies, there is »5%/year residual ASCVD risk in
patients who achieve profound LDL-C lowering (median 30 mg/dL) with combined statin and PCSK9 inhibitor
therapy. New treatment strategies are needed to target the mechanisms beyond LDL to reduce this residual
risk. Histologic studies have demonstrated that plaque neovasculature constitutes the main entrance for
inflammatory cells into plaques and provides a major source for the formation and progression of intraplaque
hemorrhage (IPH). IPH, mainly resulting from plaque neovascularization, is a common feature of advanced
atherosclerotic lesions and a critical element leading to accelerated plaque progression, plaque instability and
ischemic vascular events in humans. We found that plaque neovessel permeability (measured as Ktrans, using
dynamic contrast enhanced magnetic resonance imaging) is strongly correlated with macrophage content and
that greater adventitial Ktrans is associated with IPH. Recent studies have identified that CD163+ macrophages
are associated with IPH and can further promote neovascularization leading to IPH progression. On the other
hand, B1 cell-derived IgM can inhibit inflammation and reduce atherosclerosis, and circulating human B1 cells
are inversely associated with coronary plaque volume and instability features. Our preliminary data showed
that plasma IgM levels are reduced in patients with carotid IPH and B1 cells are inversely associated with IPH
progression. We, therefore, propose to study the role of B1 cell-derived IgM and B1 cells in IPH pathology.
To test a novel hypothesis that B1 cell-derived IgM levels are reduced in patients with IPH and that
the reduction in protective IgMs results in unobstructed IPH-promoted inflammation and neovessel
permeability, thereby exacerbating plaque progression, we propose to conduct comprehensive studies
including: (1) histological examination of CEA specimens to determine whether plaques with increased Ktrans
and/or IPH have a lower density of IgM and a higher density of CD163+ macrophages; (2) a longitudinal clinical
follow-up study in 250 patients to determine whether lower IgM levels and B1 cells predict progression of Ktrans
and IPH and whether IgM production and effect on macrophages are different in B1 cells in patients with and
without IPH; (3) in vitro mechanistic studies of endothelial sprouting and leakiness using 3D microvessels to
determine the effects of IgM and B1 cells on RBC-induced changes in macrophages and vascular permeability.
This proposal utilizes state-of-the-art imaging technique for quantification of vascular permeability and IPH
and 3D microvessels for study how hemoglobin-stimulated macrophages and B1 cells and/or IgM influence
endothelial function related vascular permeability. Our study will gain new knowledge to uncover inflammatory
mechanisms in IPH pathogenesis and to discover potential therapeutic targets with a goal of reduced vascular
permeability to prevent IPH and its progression, which will ultimately reduce residual ASCVD risk.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis
-
批准号:10580375
-
项目类别:
-
资助金额:$6.54万
-
财政年份:2022
-
负责人:Jenny E. Kanter
-
依托单位:
Role of inflammation in intraplaque hemorrhage pathogenesis
-
批准号:10615058
-
项目类别:
-
资助金额:$80.77万
-
财政年份:2022
-
负责人:Jenny E. Kanter
-
依托单位:
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis
-
批准号:10337327
-
项目类别:
-
资助金额:$38.83万
-
财政年份:2020
-
负责人:Jenny E. Kanter
-
依托单位:
Core C: Myeloid cell and atherosclerosis core
-
批准号:10450860
-
项目类别:
-
资助金额:$18.82万
-
财政年份:2020
-
负责人:Jenny E. Kanter
-
依托单位:
Core C: Myeloid cell and atherosclerosis core
-
批准号:10642743
-
项目类别:
-
资助金额:$18.87万
-
财政年份:2020
-
负责人:Jenny E. Kanter
-
依托单位:
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis
-
批准号:10713362
-
项目类别:
-
资助金额:$9.8万
-
财政年份:2020
-
负责人:Jenny E. Kanter
-
依托单位:
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis
-
批准号:10557149
-
项目类别:
-
资助金额:$38.83万
-
财政年份:2020
-
负责人:Jenny E. Kanter
-
依托单位:
Enrichment Program
-
批准号:10077868
-
项目类别:
-
资助金额:$5.23万
-
财政年份:2018
-
负责人:Jenny E. Kanter
-
依托单位:
海外基金